Dr. McCollum on Drug Sequences for Patients With CRC

A. David McCollum, MD
Published: Friday, Nov 17, 2017



A. David McCollum, MD, Baylor-Sammons Cancer Center, discusses drug sequences for patients with colorectal cancer (CRC).

Patients with CRC are generally treated with a biologic drug in combination with chemotherapy. Over time, the intensity of the chemotherapy is modified or lightened to try to maintain benefit for as long as possible.

There is still debate about which maintenance therapy is best for frontline treatment, as well as what constitutes as enough progression for a patient to need second-line therapy, says McCollum.
SELECTED
LANGUAGE


A. David McCollum, MD, Baylor-Sammons Cancer Center, discusses drug sequences for patients with colorectal cancer (CRC).

Patients with CRC are generally treated with a biologic drug in combination with chemotherapy. Over time, the intensity of the chemotherapy is modified or lightened to try to maintain benefit for as long as possible.

There is still debate about which maintenance therapy is best for frontline treatment, as well as what constitutes as enough progression for a patient to need second-line therapy, says McCollum.

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication
x